Already a member? Sign in
Category: Prescription Drugs
Most Popular Types: Symbyax
Generic Name: Fluoxetine-olanzapine
Fluoxetine-olanzapine is a combination product containing an SSRI antidepressant and an antipsychotic agent. It is used for the treatment of depressive episodes associated with bipolar I disorder and for treatment-resistant depression.
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| Bipolar Disorder | 14 | 4 |
|
|
|
|
|
| Treat my mood condition(s) | 9 | 2 |
|
|
|||
| Major Depressive Disorder | 7 | 2 |
|
|
|||
| Other | 2 | 0 | |||||
| Depressed mood | 2 | 0 | |||||
| Obsessive behavior | 1 | 0 |
See all 25 patients currently taking Fluoxetine-olanzapine
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Fluoxetine-olanzapine
| Weight gain | 5 | |
|---|---|---|
| Increased appetite | 3 | |
| Tremor | 3 | |
| didn't feel like myself | 2 | |
| Suicidal thoughts or urges | 2 | |
| Depressed mood | 2 | |
| See all 9 reported side effects ▼ | ||
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Side effects too severe | 7 | ||
| Did not seem to work | 5 | ||
| Doctor's advice | 5 | ||
| Expense | 2 | ||
| Other | 1 |
See all 12 patients who’ve stopped taking Fluoxetine-olanzapine
Adherence
Taking treatment as prescribed
Adherence of Fluoxetine-olanzapine
Always |
8 | 89% |
|
|---|---|---|---|
Usually |
1 | 11% |
|
Sometimes |
0 | 0% |
|
Never |
0 | 0% |
|
Burden
Difficulty being on treatment
Burden of Fluoxetine-olanzapine
Very |
1 | 11% |
|
|---|---|---|---|
Somewhat |
1 | 11% |
|
A little |
3 | 33% |
|
Not at all |
4 | 44% |
|
Cost
Paid out of pocket
Cost of Fluoxetine-olanzapine
$200+ |
0 | 0% |
|
|---|---|---|---|
$100-199 |
0 | 0% |
|
$50-99 |
0 | 0% |
|
$25-49 |
0 | 0% |
|
< $25 |
3 | 100% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on May 28, 2012.